BioWorld MedTech

Dec. 9, 2013

Boston Sci has favorable results for Precision Spectra SCS study

A study evaluating Boston Scientific's (Natick, Massachusetts) Precision Spectra Spinal Cord Stimulator (SCS), shows that the device provides highly significant pain relief three months after implantation. Read More

Life science VC funding seen falling behind overall funding growth rates

BSD begins selling MicroThermX microwave ablation in Turkey

Financings roundup: Physicians Trust prices 8.3M shares, seeks to raise more than $89 million

Grants roundup: QED program grants $600,000 to support four new technologies

Agreements/contracts: Boston Sci, Medicines Co. co-promote Premier stent

Med-tech Notes

Product briefs

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...